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Introduction
Alzheimer’s disease (AD) is a clinico-pathological diag-
nosis in which progressive neurodegenerative disease is 
associated with the dementia syndrome. Neuro patho-
logically, AD is generally characterised as including 
deposits of amyloid beta protein (Aβ) in senile and 
neuritic plaques [1] and neuroﬁ brillary tangles of paired 
helical ﬁ laments of hyperphosphorylated tau [2,3]. 
Currently, AD is classiﬁ ed as familial AD, which has an 
early age of onset and is associated with mutations in 
either the amyloid precursor protein (APP) or the 
presenilins (PSs), and sporadic AD, which has a later age 
of onset and a less clear aetiology [4,5]. Down’s syndrome, 
with an extra copy of APP on chromosome 21, also leads 
to a form of AD with increasing age. Th e genetic data 
associated with familial AD [6] strongly suggest that PS, 
APP and its proteolytic fragment Aβ are involved in AD 
disease progression but exactly how they contribute to 
both normal cognition and dementia is the focus of much 
debate.
Many non-genetic factors also appear to aﬀ ect disease 
initiation and progression, including diet, exercise and 
education, and many models have been proposed to 
account for their roles in AD. Population studies (for 
example, the Medical Research Council Cognitive 
Function and Aging Study [7]) demonstrate that vascular 
and AD-associated pathologies are common in people 
with and without any clinical manifestation of dementia. 
Coupled with data suggesting that the relationship 
between amyloid pathology and dementia attenuates 
with age [8], this suggests that sporadic AD especially has 
a complex disease aetiology [9].
Many models of disease progression have been proposed 
to account for the accumulating data on AD. Th ese models 
form the basis of experimental design and aﬀ ect how 
ﬁ ndings are interpreted. Data relevant to disease 
progression in AD are accumulating from many diverse 
ﬁ elds, including neuropsychology, brain imaging, 
molecular biology and genetics. Integrating these data is 
becoming harder as expertise is required in so many areas.
Th e pre-eminent model of the last few decades has 
been the amyloid cascade hypothesis [10-12], based on 
genetic data and the role of PS in the proteolysis of APP 
to release the 39 to 43 residue Aβ. Th is model proposes 
that overproduction of Aβ, or an increase in Aβ(1-42)
relative to Aβ(1-40), is causal in the disease process. In this 
model, Aβ, perhaps in a speciﬁ c aggregation state, is 
proposed as neurotoxic. An alternative interpretation of 
data relating to APP, PS and Aβ is the presenilin 
hypothesis [13], where loss or altered function of PS is 
proposed as the causal factor in disease progression. 
Abstract
Alzheimer’s disease (AD) is a progressive 
neurodegenerative disease and in its familial form is 
associated with mutations in the amyloid precursor 
protein (APP) and the presenilins (PSs). Much data 
regarding the interactions of APP, its proteolytic 
fragments and PS have been generated, expanding 
our understanding of the roles of these proteins 
in mechanisms underlying cognitive function and 
revealing many complex relationships with wide 
ranging cellular systems. In this review, we examine 
the multiple interactions of APP and its proteolytic 
fragments with other neuronal systems in terms of 
feedback loops and use these relationships to build a 
map. We highlight the complexity involved in the APP 
proteolytic system and discuss alternative perspectives 
on the roles of APP and its proteolytic fragments in 
dynamic processes associated with disease progression 
in AD. We highlight areas where data are missing and 
suggest potential confounding factors. We suggest that 
a systems biology approach enhances representations 
of the data and may be more useful in modelling both 
normal cognition and disease processes.
© 2010 BioMed Central Ltd
Relationships between the amyloid precursor 
protein and its various proteolytic fragments and 
neuronal systems
Sally Hunter* and Carol Brayne
R E V I E W
*Correspondence: seh66@medschl.cam.ac.uk
Institute of Public Health, University of Cambridge, Forvie site, Robinson Way, 
Cambridge CB2 0SR, United Kingdom
Hunter and Brayne Alzheimer’s Research & Therapy 2012, 4:10 
http://alzres.com/content/4/2/10
© 2012 BioMed Central Ltd
Other models suggest diﬀ erent initiating factors, such as 
cholesterol [14], mitochondria and apoptosis [15], insulin 
signalling and energy metabolism [16,17], cholinergic 
insuﬃ  ciency [18], Ca2+ deregulation [19,20], signalling 
decoherence [21] or a combination of multiple factors 
(for example, [22,23]). No single model adequately explains 
how APP, PS, cholesterol and other factors interact with 
synaptic plasticity, learning and memory in normal and 
disease states. Th is suggests that models currently in use 
in AD research require re-evaluation.
Recent approaches to integrating the data relevant to 
AD have involved the use of text mining, bioinformatic 
databases and network analysis for gene co-expression 
and protein-protein interactions [24-33]. Studies using 
automated interrogation of genomic and proteomic 
databases, such as UNIPROTKB [34], NCBI Entrez Gene 
[35], and IntAct [36], and text mining in literature data-
bases such as Pubmed [37] have conﬁ rmed the 
involvement of many previously highlighted neurological 
processes, extended the connectivity between known 
molecular targets and revealed new targets for investi-
gation (summarised in Table 1).
Understanding how APP contributes to synaptic 
plasticity is important in understanding normal cognition 
and disease progression in AD. Here, we approach the 
process of integrating the available data relating to the 
relationships between APP and its proteolytic fragments 
and neuronal processes based on a systems biology 
approach and build a map of relationships. We are not 
aiming to deﬁ ne protein interactions nor ﬁ nd new targets 
for investigation, but to highlight relationships in the 
existing literature that illustrate the complexity involved 
and how this relates to our current understanding of the 
role of APP in AD. We highlight areas where data are 
missing and predict relationships that may confound 
current disease models.
Building the map
Relationships involving APP and each of its proteolytic 
fragments were identiﬁ ed from literature searches using 
relevant key words. Each interaction identiﬁ ed was 
manually entered into a non-hierarchical network using 
the mapping software Compendium [38]. Th is software 
allowed each molecule or neuronal system to be 
represented as a node within the map. Each node in the 
map could contain further networks of nodes, leading to 
a multi-dimensional organisation of information. Th ese 
further nodes represented information relevant to the 
molecule of the parent node and could include notes 
describing possible relevance, questions raised and links 
to relevant entries on various bioinformatic databases. 
Th e map is not meant to be read as a protein-protein 
interaction network (PPI), but rather was designed to 
summarise and collate information relevant to the APP 
system in a more general way. Physiological outcomes, 
such as changes in signalling, were included, even though 
the precise molecular interactions are not clear. Any 
additional details, such as new biological relationships or 
new molecular interactions, can be added as they arise. 
Relationships between molecules are represented by 
connectors, with annotation if required. Figure 1 shows a 
limited map built in this way from references cited in the 
text, with additional references listed in Table 2.
Unlike more automated network studies such as that by 
Perreau and colleagues [25] where nodes were included 
in the network only if there was direct evidence of 
molecular interaction, or various studies [30-33] where 
co-expression criteria were applied, no speciﬁ c criteria 
were imposed and any relationship found was included. 
Known diﬀ erences in peptide behaviour (for example, 
[39,40]) necessitated separate nodes for Aβ(1-40) and 
Aβ(1-42). Th is was extended systematically to include all 
the peptide fragments, including P3(17-40), P3(17-42), secreted 
APP (sAPP)α and sAPPβ (the extracellular amino-
terminal fragments following α- and β-cleavage, 
respectively), C31, and so on to take account of any 
potential behavioural diﬀ erences. Th is is in contrast to 
various network constructions where the various 
proteolytic fragments are collapsed into an APP parental 
node, possibly reﬂ ecting the UNIPROTKB identiﬁ er 
(P05067) being the same for each peptide. Additionally, 
diﬀ erent aggregation states of each of the peptides 
(monomers, dimers, oligomers or ﬁ brils) were considered 
separately. Th ese additional details have been omitted 
from Figure  1 for clarity. Since there was little or no 
evidence for many of the Aβ-type peptides [41], these 
were collapsed into a separate node (not shown).
Th e relationships in Figure  1 were analysed manually 
by identifying feedback loops. Direct feedback loops were 
deﬁ ned as relationships between APP, any of its proteo-
lytic fragments and any other molecule or functional 
change that was represented at more than one point in 
the map. Possible indirect feedback loops between any 
neural system, such as neurotransmitter signalling, Ca2+ 
homeostasis or the inﬂ ammation cascade, were also 
investi gated by looking for molecules or functional change 
in these systems that interact with APP or any of its 
proteolytic fragments at more than one point in the map.
Following a brief summary of APP cleavage, two 
examples of the relationships between APP pathways and 
neuronal processes, looking at the extracellular matrix 
(ECM) and endocytosis, serve to illustrate the implica-
tions of the complexity involved.
The amyloid precursor protein
Overview
APP is a type I transmembrane protein [42] with a large 
extracellular amino-terminal domain, a transmembrane 
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domain and an intracellular carboxy-terminal domain 
that resembles a cell surface receptor [43]. It is expressed 
in several isoforms, with APP695 the main isoform ex-
pressed by neurons. APP has a high turnover, with a half 
life ranging from approximately 1  hour [44-46] to 
approximately 4  hours [47-49]. In addition to its func-
tions at the cell surface, full length mature APP is also 
processed via competing pathways that release proteo-
lytic fragments [5,43,50] (recently reviewed in [51]). In 
eﬀ ect there are four possible routes: APP may remain 
functionally active at the cell surface; it may be 
internalised and recycled or degraded; it may be cleaved 
via the α-pathway, releasing the sAPPα fragment, leaving 
the membrane bound C83 carboxy-terminal fragment 
that is further processed to the P3 fragment; or it may be 
cleaved via the β-pathway releasing sAPPβ, leaving the 
membrane bound C99 carboxy-terminal fragment that is 
further processed to the Aβ fragment.
As can be seen in Figure 1, α- and β-cleavage pathways 
(numbered  1 and 2, respectively) converge on a further 
intramembrane γ-cleavage (numbered  3) by the PS-
containing γ-secretase complex to release the variable 
length Aβ and P3 peptides and the variable length APP 
intracellular domain (AICD). Additional cleavages, in-
clud ing caspase cleavage of the carboxyl terminus at 
residue D664 of APP695, producing the alternative length 
carboxy-terminal fragment C31 [51], and cleavage by 
BACE2 (beta-site amyloid precursor protein cleaving 
enzyme 2) within the Aβ sequence [52], have been omitted 
for clarity.
Unprocessed APP is degraded or recycled via the 
endosomal or lysosomal pathways and may be recycled 
back to the membrane and processed within approxi-
mately 30  minutes [46], with perhaps a third to a half 
being processed via the cleavage pathways as measured 
by secreted sAPPα/β [46]. Regulatory relationships 
Table 1. Overview of protein-protein interaction network studies
Reference Selection criteria Exclusion criteria Main focus
[25] Evidence of direct interaction 
between molecules from literature 
searches
Metals, non-protein molecules, 
poorly characterised proteins, specifi c 
peptides are included as parent 
genes
Direct PPI involving APP and associated fragments by domain 
with reference to APP770 isoform but with application to all 
isoforms; molecular networks with reference to biological 
processes
[33] Twelve causative or susceptibility 
‘seed’ genes previously associated 
with AD; candidate genes were 
selected due to close proximity to 
GWAS-identifi ed gene loci associated 
with AD
Proteins lacking open reading 
frames; transcription factors, highly 
glycosylated proteins, extracellular 
proteins, proteins containing several 
transmembrane regions; co-
expression data were used as a fi lter
Identifi cation of genes in AD with reference to direct PPI and 
biological processes
[31] Co-expressed genes that diff er 
between controls and AD 
Probe-sets not mapping to any gene 
or mapping to hypothetical proteins 
were removed
Variations in transcriptomes of AD suggest similarities with 
molecular networks associated with CVD and diabetes. 
Cis-regulatory elements identifi ed in several diseases known to 
co-occur with AD
[30] Genes with variable expression 
between an AD and an aging 
microarray study
Arrays that signifi cantly varied 
between subjects in each study 
group; outlier removal, unreliable 
probe sets defi ned as being present 
in three or fewer arrays; control probe 
sets and probes not associated with 
known genes
Transcriptional changes between AD and aging highlight 
possible contributors to disease pathways. Many biological 
processes are shared between AD and aging. Many novel 
associations found, including MAPK pathways and unknown 
proteins. New functional and disease related association for 
PSEN1 with glial/neuronal interactions; confi rms and highlights 
gamma14.3.3 signalling in AD 
[32] Genes with variable expression 
between human and mouse from 
brain sample microarray gene 
expression data sets
Outlier removal, fi ltered (method 
not specifi ed) to remove datasets 
with low interspecies expression or 
low connectivity correlations; only 
top 5,000 Human and 3,000 Mouse 
connected genes included, rest 
removed to reduce ‘noise’
Mouse and human networks are highly similar with expression 
levels more preserved than connectivity. Signifi cant 
species diff erence in: i) co-expression arrays from astroglia 
and microglia but not neurons; ii) the role of PSEN1 in 
oligodendrocytes and myelination; and iii) further evidence 
of species diff erence in glial cells linked to neuroinfl ammation 
in human AD. Neuronal death is a small part of the biological 
changes associated with AD in this dataset; new transcription 
factors associated with AD
[27] All AD and related pathways in KEGG 
database with co-expression data
Genes without corresponding data 
in the assembled PPI network and 
proteins with no corresponding 
genes in the co-expression data
Crosstalk between pathways involved in AD; close relationships 
between APP and apoptosis, Notch, Wnt pathways and 
cytokine-cytokine interactions in this dataset, brain areas vary 
in specifi c pathway relationships and order of signifi cance
AD, Alzheimer’s disease; APP, amyloid precursor protein; CVD, cardiovascular disease; GWAS, genome-wide association study; KEGG, Kyoto Encyclopedia of Genes and 
Genomes; MAPK, mitogen-activated protein kinase; PPI, protein-protein interaction; PSEN, presenilin.
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promoting expression or cleavage have been collapsed 
into summary boxes in Figure 1 for simplicity.
Complex feedback pathways involving APP and its 
proteolytic fragments; the extracellular matrix and 
endocytosis
The extracellular matrix
APP interacts with itself and its own proteolytic frag-
ments at many points in the network with various 
functional consequences. At the cell surface, the large 
amino-terminal domain of full length APP interacts with 
many components of the ECM, including heparins and 
heparin sulphate proteoglycans [42], laminin, collagen 
[53,54] and β-1-integrin [43,55,56], and contributes to 
early neuronal development, axon and neurite growth, 
cell adhesion and synaptic plasticity [43,57]. Many of 
these interactions are now represented in MatrixDB [58], 
an ECM interaction database.
Th e amino-terminal domain of APP binds heparin in a 
pH- and zinc-dependant manner and this binding pro-
motes the formation of APP homodimers [42,59-61]. 
Depending on various factors, including cell compart-
ment and pH, this dimerisation may inﬂ uence APP 
proteolysis via α- or β-cleavages due to confor mational 
changes [59], though this requires further investigation.
Th e large amino-terminal fragment released by α-
cleavage, sAPPα, is a soluble monomer. It retains two 
heparin binding sites and has been shown to bind heparin 
as a dimer [60]. Th e ability of sAPPα to disrupt APP 
dimerisation at the cell surface is thought to contribute to 
Figure 1. A limited map of amyloid precursor protein relationships showing molecules/neuronal systems as nodes and interactions 
between them as arrows. Evidence for each relationship is summarised in Table 2. Numbers are referred to in the text. Aβ, amyloid beta protein; 
Abl, tyrosine-protein kinase ABL1; AChR, acetylcholine receptor; ADAM, a disintegrin and metalloproteinase domain-containing protein; AICD, 
APP intracellular domain; Akt, RAC-alpha serine/threonine-protein kinase; AMPAR, AMPA receptor; ApoE, apolipoprotein E; APP, amyloid precursor 
protein; BACE, beta-site amyloid precursor protein cleaving enzyme; CD74, HLA class II histocompatibility antigen gamma chain; ECM, extracellular 
matrix; IDE, insulin degrading enzyme; JIP1, C-Jun-amino-terminal kinase-interacting protein 1; JNK, C-Jun amino-terminal kinase; Lyn, tyrosine-
protein kinase Lyn; PKA, protein kinase A; PKC, protein kinase C; LRP, low-density lipoprotein receptor; LTP, long-term potentiation; mAChR, 
muscarinic acetylcholine receptor; mGluR, metabotropic glutamate receptor; nAChR, nicotinic acetylcholine receptor; NMDAR, NMDA receptor; 
P2Y2, P2Y purinoceptor 2; PI3K, phosphoinositide 3-kinase; sAPP, secreted amyloid precursor protein; Src, proto-oncogene tyrosine-protein kinase 
Src; TIMP, tissue inhibitor of metalloproteinases; TNF, tumour necrosis factor.
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Table 2. Additional references supporting the network diagram in Figure 1
Factor Details Reference
Akt Aβ increases Akt phosphorylation in the short term via a mechanism involving α7-nAChR and NMDARs, with  [99]
 phosphorylation levels returning to baseline over the long term
AMPA receptors AMPA glutamate receptor density is reduced by Aβ oligomers via reduction of CamKII [100,101]
ApoE Decreased levels of ApoE lead to increased β-cleavage [102]
 ApoE promotes polymerisation of Aβ into fi brils and enhances fi brillar Aβ deposition in neuritic plaques.  [103-105]
 The high affi  nity binding of Aβ to ApoE reduces ability of ApoE to bind lipids
Ca2+ sAPPα modulates Ca2+ signalling by activating high conductance K+ channels via a mechanism dependent on cGMP [106]
CD74 Interacts with APP and reduces expression of Aβ [107]
Cholesterol Interactions of cholesterol and APP may allow APP to react to cholesterol status of the cell [108]
 Membrane cholesterol correlates with β-secretase activity and inhibition of β-secretase activity leads to  [109,110]
 increased membrane cholesterol levels. Moderate reductions in cholesterol enhance the co-expression of APP 
 and BACE1 and promote the production of Aβ
 Aβ binds lipids and has high affi  nity for cholesterol. Aggregated Aβ(1-40) may aff ect lipid transport.  [111,112]
 Aβ binds 24-hydroxycholesterol and aff ects membrane choline carriers
Complement cascade Aβ activates neuronal complement cascade to induce the membrane attack complex and reduces  [113]
 complement regulatory proteins, increasing complement-mediated cytotoxicity
Dishevelled Dvl-1 increases sAPPα production mediated via JNK and PKC/MAPK but not via p38 MAPK [114]
Electrophysiology Hippocampal and cortical electrophysiological processes are modulated by sAPPα [115]
 Aβ(1-40) suppresses epileptiform activity in hippocampal neurons [116]
Fe65 APP binds Fe65 at the YENPTY sequence with eff ects on gene transcription, cytoskeleton and cell motility.  [117-121]
 Binding of Fe65 to APP is dependent on phosphorylation state of Y682; phosphorylation of T668 reduces the 
 binding of Fe65 to YENPTY. Binding of Fe65 reduces Aβ
Furin Furin enhances cleavage to active forms of ADAM10 and ADAM17, leading to enhanced α-cleavage [122]
Glucose/glutamate  sAPPα enhances transport of glucose and glutamate in synapses and protects from oxidative stress via a [123]
transport mechanism involving cGMP
Glutamate signalling sAPPα suppresses NMDA currents rapidly and reversibly at concentrations of approximately 0.011 nM, possibly  [124,125]
 involving cGMP and a protein phosphatase. Reductions in sAPPα lead to reduced tetanically induced NMDA 
 currents while increased sAPPα increased these currents and enhanced LTP
G-protein signalling Aβ directly increases TNF-α at high levels and at low levels increases TNF-α release by altering GPCR signalling  [126]
 at early stages of disease progression by indirect eff ects on GPCR kinase 2/5
 Full length and processed APP can potentially interact with G proteins via the cytoplasmic tail and this can be  [127-129]
 altered by APP mutations around the G protein binding site. This interaction has the potential to alter G-protein 
 signalling with wide ranging eff ects, including Ca2+ regulation and cell cycle pathways
HDL Aβ binds ApoA-I, ApoA-II, ApoE and ApoJ; binding modulates Aβ solubility [130]
Heparins Proteolysis of immature BACE1 to its mature active form is promoted by low concentrations of heparin and  [70,131,132]
 inhibited at higher concentrations. Certain heparin derivatives may act as inhibitors of BACE1 and have 
 therapeutic potential
IL-1β Enhanced α-cleavage by ADAM10/17 via up-regulation of P2Y2 receptors and may increase levels of  [133,134]
 ADAM10/17 by approximately threefold
 Increases expression of APP and β-cleavage in astrocytes [135]
Insulin degrading  Aβ competes with insulin for IDE and reduced IDE availability may contribute to dementia [136]
enzyme
Integrins sAPPα competes with APP for binding sites on integrin-β-1 and promotes neurite outgrowth [137]
 Aβ binds focal adhesion molecules and integrins and modulates integrin/FA signalling pathways involved in  [138,139]
 cell cycle activation and cell death. The αv integrin subunit is required for Aβ-associated suppression of LTP
Lipids Binding of Aβ to acidic lipid molecules promotes Aβ aggregation. Aβ binds membrane gangliosides,  [140-142]
 sphingolipids and cholesterol, which enhance Aβ aggregation
 Association of APP and BACE1 with lipid rafts increases Aβ [143]
 Aβ endocytosis may also involve lipid rafts [144]
 Sphingolipids enhance α-cleavage via MAPK/ERK signalling [145]
Continued overleaf
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its neuroprotective actions [62-64] and may partly 
explain why sAPPα is approximately 100 times more 
neuroprotective against excitotoxicity, glucose depriva-
tion and the addition of Aβ in hippocampal cultures than 
sAPPβ, which lacks the second carboxy-terminal heparin 
binding site [63]. Dementia status has been associated 
with both reduced sAPPα levels in cerebrospinal ﬂ uid 
[65] and an increased half life of sAPPα [49].
Diﬀ ering by only 16 carboxy-terminal residues, sAPPα 
and sAPPβ share a high degree of sequence homology 
and have the potential to compete with each other for 
binding sites. Since both sAPPβ and sAPPα are constantly 
present in the ECM in dynamically changing ratios, we 
predict that sAPPβ could act as an antagonist of sAPPα/
APP (shown in Figure 2 as competitive inhibition (line 1)), 
with the potential to modulate various interactions 
between APP and sAPPα and the ECM. We predict, 
therefore, that any functional outcome from the 
interactions of the APP pathway will depend on the 
synergy between APP and its amino-terminal fragments.
Table 2. Continued
Factor Details Reference
LTP Aβ suppresses LTP in hippocampal neurons via a mechanism involving α4β2 nAChRs; Aβ aff ects cascades  [146,147]
 downstream of NMDA GluR signalling
Muscarinic ACh  Increases in mAChR-M1 and -M3 activation upregulate α-cleavage via PKC activation. Muscarinic upregulation [75,148-151]
signalling of sAPPα secretion may involve the activation of a Src tyrosine kinase, leading to activation of PKCα and ERK1/2. 
 Increased M2 activation decreases sAPPα secretion
 Inhibition of muscarinic signalling promotes APP processing via β-pathway. Increased M1/M3 signalling  [152,153]
 promoted β-cleavage via PKC; MEK/ERK and increased expression of BACE1; M2 activation suppressed 
 BACE expression
MAPK/ERK signalling MAPK cascade may mediate the independent eff ects of PKC and tyrosine kinase in human astrocytes [154]
Neurite outgrowth APP enhances neurite outgrowth independently from sAPPα [155]
NF-κB May reduce expression of BACE1 [156]
 NF-κB upregulation by capacitive Ca2+ entry enhances sAPPα release via mAChR signalling [157]
Nicotinic ACh signalling  Aβ(1-40) and Aβ(1-42) reduced Α4β2 nAChR and α7 nAChR currents. Aβ(1-40) but not Aβ(1-42) increased glutamatergic  [40,158]
 AMPA. Signalling via Α4β2 nAChR is associated with reduced Aβ
 Aβ has high affi  nity for the α7 nAChR and this may be associated with increased Aβ accumulation. Diff erential  [39,159,160]
 eff ects of Aβ(1-40) and Aβ(1-42) on α7 nAChR as seen by diff erent eff ects on ACh release and Ca
2+ infl ux. Disruption 
 of signalling by α7 nAChR may be associated with Aβ-mediated increases in pre-synaptic Ca2+
 Aβ(1-42) has approximately 5,000-fold greater affi  nity for α7 nAChR than for Α4β2 nAChR [161]
NMDA GluR Aβ promotes endocytosis of NMDARs in cortical neurons with the involvement of protein phosphatase 2B  [162]
 and the tyrosine phosphatase STEP
Nucleotide signalling  G-protein-coupled purine receptor, P2Y2 enhanced the release of sAPPα in a time- and dose-dependent [163]
via P2Y2 receptors manner; probably mediated via ADAM10 and ADAM17
numb APP binds numb when Y682 is unphosphorylated and inhibits Notch signalling [164]
PKA/CREB Aβ inhibits PKA via increased persistence of its regulatory subunit PKAIIα, resulting in reduced CREB  [73]
 phosphorylation in response to glutamate
PKC PKC activators enhance α-cleavage [165,166]
 Aβ inhibits PKC [167]
Reelin Reelin interacts with APP and Α3/β1-integrins and promotes neurite extension; APP endocytosis is reduced.  [56,168]
 Reelin signalling opposes the actions of Aβ
Src, Abl, Lyn, JNK/JIP1 These tyrosine kinases bind to APP when phosphorylated at Y682 with affi  nity increased by phosphorylation of  [169,170]
 T668. JNK phosphorylation of APP at T668 modulated by JIP1
TIMP-3 Increases in TIMP-3 led to decreased surface expression of ADAM10 and APP. The production of Aβ and CTF  [171]
 is increased. TIMP-3 appears to promote endocytosis and β-secretase cleavage
Transthyretin Neuroprotection in transgenic mice over-expressing mutant APP is associated with elevated levels of  [172,173]
 transthyretin and sAPPα and may be linked to increased proteolysis of Aβ
Aβ, amyloid beta protein; ACh, acetylcholine; ADAM, a disintegrin and metalloproteinase domain-containing protein; Akt, RAC-alpha serine/threonine-protein 
kinase; AMPA, 2-amino-3-(5-methyl-3-oxo-1,2- oxazol-4-yl)propanoic acid; ApoE, apolipoprotein E; APP, amyloid precursor protein; CamKII, calcium/calmodulin-
dependent protein kinase type II; CD74, HLA class II histocompatibility antigen gamma chain; CREB, cyclic adenosine monophosphate response element-binding; CTF, 
carboxy-terminal fragment; ERK, extracellular signal-regulated kinase; FA, fatty acids; GluR, glutamate receptor; GPCR, G-protein-coupled receptor; HDL, high-density 
lipoprotein; IDE, insulin degrading enzyme; JIP1, C-Jun-amino-terminal kinase-interacting protein 1; JNK, C-Jun amino-terminal kinase; LTD, long-term depression; 
LTP, long-term potentiation; Lyn, tyrosine-protein kinase Lyn; MAPK, mitogen-activated protein kinase; mAChR, muscarinic acetylcholine receptor; MEK, ERK activator 
kinase; nAChR, nicotinic acetylcholine receptor; NMDAR, NMDA receptor; P2Y2, P2Y purinoceptor 2; PKA, protein kinase A; PKC, protein kinase C; sAPP, secreted 
amyloid precursor protein; Src, proto-oncogene tyrosine-protein kinase Src; TIMP, tissue inhibitor of metalloproteinases.
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Aβ interacts with heparins in the ECM and at high 
levels may prevent the catabolism of proteoglycans and 
promote amyloid formation [66]. Reciprocally, heparins 
modulate many of the interactions involving Aβ. Heparins 
enhance both nucleation and elongation processes in the 
aggregation of Aβ [67] and modulate interactions of Aβ; 
for example, heparins can limit the neurotoxic and pro-
inﬂ ammatory activity of Aβ in a dose-dependent manner 
[68]. Additionally, heparins contribute to the uptake of 
Aβ by a pathway shared with apolipoprotein E [69] and 
also contribute to the regulation of the β-secretase BACE 
in a dose-dependent manner, with low concentrations 
promoting and high concentrations inhibiting the 
activation of BACE1 [70].
In terms of direct feedback, Aβ may be part of a 
negative feedback loop involved in the regulation of APP 
expression and the promotion of α-cleavage. Fibrillar 
forms of various proteins, including Aβ, interact with 
amino-terminal APP and increase APP expression [71] 
(Figure 2, line 2) and Aβ(1-40) may up-regulate expression 
of α-secretase via integrin receptors and matrix metallo-
proteinase-9 activity [72] (Figure 2, line 3). Additionally, 
Aβ has many indirect negative feedback relationships 
with α-cleavage - for example, Aβ inhibits protein kinase 
C [73] and insulin signalling [74], both involved in up-
regulation of α-cleavage [75] (Figure  2, line  5)  - and 
additionally may negatively feedback on APP expression 
and its own production via a pathway involving Fe65 and 
glycogen synthase kinase 3 [76]. Reciprocally, changes to 
gene expression by sAPPα via the activation of NF-κβ 
may attenuate the interactions of Aβ [77] and this can be 
understood as reciprocal indirect feedback from the α-
pathway on the β-pathway (Figure 2, line 4).
Th e data reviewed above suggest that Aβ may contri-
bute to both direct and indirect feedback loops in the 
ECM at multiple points, with consequences for the 
interactions of APP, sAPPα, Aβ and sAPPβ that may 
ultimately aﬀ ect cell adhesion, neurite outgrowth and 
synaptic plasticity. Th ese eﬀ ects will depend on the 
speciﬁ c sequence length, concentration and aggregation 
state of the Aβ-type peptides, which may dynamically 
change in response to the neuronal environment.
Endocytosis
Increases in endocytosis, often associated with synaptic 
activity, lead to both an increase in Aβ [78] and a 
reduction in α-cleavage and lower secreted sAPPα levels 
[79]. Th is may reﬂ ect the regulatory role of compart men-
tation in APP proteolysis, where α-cleavage occurs at the 
cell surface and Aβ production is associated with factors 
that promote endocytosis. No studies could be found 
investigating the role of endocytosis on P3 production, so 
this cannot be discussed speciﬁ cally. Endocytosis allows a 
degree of dissociation between the α- and β-cleavages 
and γ-cleavage, resulting in levels of sAPPα and sAPPβ 
that may be independent of Aβ(1-40/42) and P3 levels, 
respectively. Th is means that in terms of function, APP 
processing via the β-pathway has the potential to either: 
modulate actions of sAPPα via competition with sAPPβ; 
or modulate the actions of sAPPα and initiate actions 
mediated by Aβ.
P3 corresponds to Aβ(17-40/42) and we predict that this 
shared sequence could allow P3 to modulate the inter-
actions of Aβ (shown in Figure  2 as competitive 
inhibition), especially where those interactions involve 
the carboxy-terminal amino acids. While no studies can 
be found that address this particular question directly, 
various amino-terminal truncated forms of Aβ have 
been associated with diﬀ use plaques [80,81] and the 
Aβ(17-40) fragment, corresponding to P3, has been 
studied in terms of aggregation [82]. It is clear that 
amino-truncated Aβ peptides, including P3, have 
potential for aggregation and can interact with Aβ, but 
how this aﬀ ects the physiological behaviour of neuronal 
systems is not clear. In terms of functional ﬂ ow through 
the APP pathway, processing via the α-pathway to 
release sAPPα and P3 could either: initiate actions of 
sAPPα; or initiate actions of sAPPα and modulate 
actions mediated by Aβ.
In terms of modelling these interactions in functional 
contexts, PPI networks may require a more detailed 
approach, where each sequence length and aggregation 
state is represented as an individual node.
The eff ects of concentration, sequence length aggregation 
state and affi  nity
Aβ is produced in a range of sequence lengths [41] and 
can form monomers, dimers, oligomers and ﬁ brils. Th e 
amount of Aβ produced is regulated and can dynamically 
change in response to many factors, including increased 
cholesterol [83], increased synaptic activity [84], heparins 
via activation of BACE1 [70], reduced acetylcholine (Ach) 
signalling via muscarinic receptors [70], sustained 
increased cytosolic Ca2+ [85], and hypoxia [86]. Changes 
in concentration are a well recognised mechanism of 
regulation in cellular processes; for example, Aβ(1-40) and 
Aβ(1-42) both promote angiogenesis at nanomolar concen-
trations but inhibit it at higher micromolar concentra-
tions [87].
Diﬀ erent sequence lengths show diﬀ erent behaviours; 
for example, Aβ(1-42) is more prone to aggregation than 
Aβ(1-40) due to a more rigid carboxyl terminus [88]. Aβ 
monomers appear to have structured and unstructured 
regions, with diﬀ erences in aqueous conformations 
between Aβ(1-40) and Aβ(1-42) [89]. While both Aβ(1-40) and 
Aβ(1-42) reduced currents via α7 and α4β2 ACh receptors 
(AChRs), only Aβ(1-40) increased glutamatergic signalling 
via AMPA receptors [40]. Another study found that the 
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Figure 2. Feedback between amyloid precursor protein and its proteolytic fragments. Inhibition is shown in red, enhancement in green; 
numbers are referred to in the text. Functionally diff erent aggregation states for the Aβ-type peptides are collapsed into P3 and Aβ nodes for clarity. Aβ, 
amyloid beta protein; AICD, APP intracellular domain; APP, amyloid precursor protein; PKC, protein kinase C; sAPP, secreted amyloid precursor protein.
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eﬀ ects of Aβ(1-40) and Aβ(1-42) on α7 AChRs, as measured 
by ACh release and Ca2+ inﬂ ux, were diﬀ erent [39]. 
Additionally, Aβ(1-40) may protect neurons from the eﬀ ects 
of Aβ(1-42) by disrupting the aggregation of Aβ(1-42) [90] and 
this raises the possibility that P3-type peptides may act in 
similar ways. Th e functional eﬀ ects of sequence length 
are only just beginning to be elucidated and should be 
expanded to include all the Aβ-type peptides, including 
P3. In addition to diﬀ erences in peptide sequence and 
concentration, aggregation state also modulates function. 
Aβ oligomers appear to be spherical [91,92] and Aβ ﬁ brils 
appear as ﬁ ne ﬁ bres [92]. Aβ oligomers, but not mono-
mers or ﬁ brils, enhance lipid release [93] and at low 
concentrations enhance neuronal diﬀ erentiation [92] 
whereas Aβ ﬁ brils, but not monomers or oligomers, may 
interact with APP and increase its expression [71]. While 
both soluble and aggregated forms of Aβ(1-40) inhibit long-
term potentiation, the ﬁ brillar forms may additionally 
aﬀ ect neurotransmitter release [94].
Within a speciﬁ c cellular compartment, whether one 
interaction is more likely to occur than another depends 
on the relative aﬃ  nities of the reactants involved. While 
dissociation constants have been measured for some 
reactions in rodent models (for example, K(i) values of 
Aβ(1-42) for α7 nicotinic AChRs from rat and guinea pig 
are 4.1 and 5.0  pM, respectively, and the K(i) of Aβ(1-42) 
with α4β2 AChRs is approximately 5,000-fold lower at 30 
and 23 nM, respectively [95]), we are missing dissociation 
constants for most interactions in humans.
Taken together, the data discussed above suggest that 
the interactions of APP and its proteolytic fragments 
with synaptic systems are complex and involve subtle 
changes in the relative ratios between APP and all its 
fragments. Given the complexity of the APP system, 
multiple neuronal systems have the potential to regulate 
the expression and proteolysis of APP and could also 
initiate imbalance within this system, leading to multiple 
possible disease pathways.
Th is complexity has the potential to confound purely 
empirical studies into the behaviour of the peptides in 
model systems. Over-expressing Aβ peptides in, for 
example, mouse models without knowing their concen-
trations, sequences and aggregation states and the 
background concentrations, sequences and aggregation 
states of the other relevant peptides in the experimental 
system that is being studied means that we do not know 
if the experimental results obtained are due to the 
properties of the Aβ peptides themselves or reﬂ ect a 
disrupted balance in a complex system over time, or 
perhaps both. While this distinction may seem subtle, 
given the self-organising and self-referencing properties 
of the human brain, an approach based on the principles 
in systems biology may better represent the roles of the 
APP pathway in functional contexts.
Discussion
It is not possible to include the full extent of the known 
interaction of APP and its proteolytic fragments here and 
further interactions may yet be discovered. Data relating 
to the roles of APP and its proteolytic fragments in 
synaptic plasticity and AD have accumulated from many 
diverse ﬁ elds and these need to be placed into context. 
One way of doing this is to investigate the relationships 
between APP, its proteolytic fragments and wider 
neuronal systems by mapping networks of interactions.
It is interesting that the networks generated in the 
various studies reviewed in Table 1 do not always overlap 
and diﬀ erent studies highlight diﬀ erent pathways or 
biological processes, for example, Fe2+ [28], apoptosis 
[96], or cardiovascular disease/diabetes [31]. Each study 
has diﬀ erent starting points, inclusion/exclusion criteria 
and network construction methods, so this lack of 
agreement is no surprise. It is diﬃ  cult to assess the 
degree to which the various starting points, criteria and 
network construction methods bias results towards an 
outcome.
Th e study by Soler-Lopez and colleagues [33] may not 
model the interactions of full length APP in the 
membrane adequately, as many of the ECM proteins that 
might be expected to interact are excluded due to 
diﬃ  culties involved in expressing them in the experi-
mental microarray used. Th is may shift the focus of their 
network more towards intracellular interactions. Given 
the importance of the various interactions of APP with 
components of the ECM, any study excluding such 
proteins and proteoglycans could be seriously confounded.
While the study by Perreau and colleagues [25] maps 
PPIs to speciﬁ c domains of full length APP, they do not 
distinguish between the diﬀ erent proteolytic peptides. 
Additionally, transient interactions and biologically 
essential post-translational modiﬁ cations, such as glyco-
sylation and phosphorylation, cannot yet be fully repre-
sented in PPI networks [27], severely limiting the 
modelling of regulation and control in these models.
Studies comparing mouse and human gene expression 
networks [32] or aging and AD pathways [30] have 
revealed interesting results. Perhaps most striking is the 
study revealing a human-speciﬁ c network for PS function 
in oligodendrocytes and myelination, with the potential 
to confound the current approach to modelling AD in 
rodents [32]. Miller and colleagues [30,32] also show 
important contributions from both neuronal and glial 
pathways, perhaps reﬂ ecting the contributions of glia to 
disease pathways found in humans [97,98]. Th e diﬀ er-
ences found in networks between glia and neurons could 
be extended to diﬀ erentiate between speciﬁ c neuronal 
types and future network models may usefully investigate 
why cholinergic neurons in AD appear more susceptible 
to degeneration than others.
Hunter and Brayne Alzheimer’s Research & Therapy 2012, 4:10 
http://alzres.com/content/4/2/10
Page 9 of 14
We do not yet have totally inclusive, gene co-expression 
or PPI models of APP and related pathways to the level of 
detail required and this places limitations on their 
interpretation. Given the limitations, however, network 
studies do show the usefulness of the systems biology 
approach in integrating huge volumes of data and a 
simple search of patents in Google with the terms 
‘protein interaction network Alzheimer disease’ retrieves 
more than 700 applications based on this approach. 
Network studies highlight the idea that multiple pro-
cesses are involved in AD disease pathways, reveal new 
targets for further investigation and have generated new 
hypotheses. Network models have the potential to avoid 
biases inherent in other approaches, such as the emphasis 
on Aβ in animal models based on the more reductionist 
amyloid cascade hypothesis, and allow multiple disease 
pathways to be represented in a single model, perhaps 
better relating to the processes involved in human 
disease.
We have suggested that APP and its proteolytic 
fragments appear to dynamically modulate each other by 
multiple mechanisms with evidence for both direct and 
indirect feedback loops between Aβ, sAPPα, sAPPβ and 
full length APP. Additionally, the fragments derived from 
γ-cleavage, including the variable length fragments, P3 
and Aβ, have the potential to interact with each other 
and modulate multiple neuronal processes in subtle and 
dynamic ways. Unfortunately, evidence for the role(s) of 
P3 is almost entirely missing from the literature and that 
for sAPPβ is limited. Without this information, we 
cannot have a full picture of the contributions of the APP 
proteolytic system to normal neuronal processes and 
how these change during disease progression.
Given the number and range of reciprocal feedback 
relationships that APP and its proteolytic fragments are 
involved in, the eﬀ ects of perturbing the APP proteolytic 
system may be better understood as dynamic, synergistic 
actions involving multiple players. A wide range of 
neuronal processes have the potential to interact with 
and regulate APP processing, allowing APP to monitor 
the current state of the cell. Th e multiple proteolytic 
pathways allow APP to assimilate signals from wide-
ranging cellular systems and pass these signals on via the 
ratios of APP fragments. Th e constant turnover of APP 
contributes to the ability of neurons to sense the current 
state of the cell and use this information to set in motion 
future responses. Th e potential for subtly diﬀ erent signals 
both from the α- and β-pathways via alternative peptides 
and the complex feedback relationships between them 
described above ﬁ ts well with the ﬁ ne control required 
for integrating neuronal systems.
Th e predicted synergy between APP and all its 
proteolytic fragments implies that the ratios of full length 
APP and all the various fragments, not just Aβ(1-40) and 
Aβ(1-42), are more important than absolute levels in 
coordinating neuronal responses. Th e complexity of the 
relationships described here has the potential to con-
found purely empirical investigations into the activities of 
any one proteolytic fragment studied in isolation. To 
avoid these predicted confounding eﬀ ects, experimental 
approaches should be extended to account for the 
diﬀ erent concentrations, aﬃ  nities and aggregation states 
of each peptide length, and experimental systems should 
be followed over time for each biological process in a 
systematic manner. With over 40 Aβ-type peptides [41], 
this presents a challenge.
Generating useful network models will require a more 
detailed and comprehensive approach to experimental 
design, involving a range of experimental controls to 
account for all the confounding factors. Th ese data will 
be essential for generating network models that are truly 
relevant to our understanding of normal and abnormal 
processes in the context of the human population.
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